DE69726255D1 - Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung - Google Patents

Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung

Info

Publication number
DE69726255D1
DE69726255D1 DE69726255T DE69726255T DE69726255D1 DE 69726255 D1 DE69726255 D1 DE 69726255D1 DE 69726255 T DE69726255 T DE 69726255T DE 69726255 T DE69726255 T DE 69726255T DE 69726255 D1 DE69726255 D1 DE 69726255D1
Authority
DE
Germany
Prior art keywords
valaciclovir
pharmaceutically acceptable
acceptable salt
genital herpes
suppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69726255T
Other languages
English (en)
Other versions
DE69726255T2 (de
Inventor
John Delehanty
L Smiley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24399659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69726255(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69726255D1 publication Critical patent/DE69726255D1/de
Application granted granted Critical
Publication of DE69726255T2 publication Critical patent/DE69726255T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69726255T 1996-01-19 1997-01-17 Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung Expired - Lifetime DE69726255T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59944896A 1996-01-19 1996-01-19
US599448 1996-01-19
PCT/EP1997/000192 WO1997025989A1 (en) 1996-01-19 1997-01-17 Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application

Publications (2)

Publication Number Publication Date
DE69726255D1 true DE69726255D1 (de) 2003-12-24
DE69726255T2 DE69726255T2 (de) 2004-08-26

Family

ID=24399659

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69726255T Expired - Lifetime DE69726255T2 (de) 1996-01-19 1997-01-17 Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung

Country Status (12)

Country Link
EP (1) EP0874631B1 (de)
JP (1) JP4097698B2 (de)
AT (1) ATE254463T1 (de)
AU (1) AU722304B2 (de)
CA (1) CA2243237C (de)
CY (1) CY2512B1 (de)
DE (1) DE69726255T2 (de)
DK (1) DK0874631T3 (de)
ES (1) ES2210490T3 (de)
PT (1) PT874631E (de)
WO (1) WO1997025989A1 (de)
ZA (1) ZA97400B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
ITMI20010009A1 (it) * 2001-01-03 2002-07-03 Menarini Ricerche Spa Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera
US6849736B2 (en) * 2001-09-07 2005-02-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
EP1465894A4 (de) * 2001-11-14 2008-10-08 Teva Pharma Synthese und reinigung von valacyclovir
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
GB0605344D0 (en) * 2006-03-17 2006-04-26 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
JP4669804B2 (ja) * 2006-03-28 2011-04-13 株式会社オーディオテクニカ コンデンサマイクロホン
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
CN104188928B (zh) * 2014-09-17 2017-07-28 山东新时代药业有限公司 一种盐酸伐昔洛韦片剂及其制备方法
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN109651371B (zh) * 2018-12-31 2021-02-23 辰欣药业股份有限公司 一种盐酸伐昔洛韦的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
CA2243237A1 (en) 1997-07-24
EP0874631B1 (de) 2003-11-19
ZA97400B (en) 1997-11-13
JP4097698B2 (ja) 2008-06-11
WO1997025989A1 (en) 1997-07-24
CY2512B1 (en) 2005-12-23
JP2000503310A (ja) 2000-03-21
CA2243237C (en) 2008-09-02
EP0874631A1 (de) 1998-11-04
PT874631E (pt) 2004-04-30
DK0874631T3 (da) 2004-03-22
ES2210490T3 (es) 2004-07-01
AU1443497A (en) 1997-08-11
DE69726255T2 (de) 2004-08-26
AU722304B2 (en) 2000-07-27
ATE254463T1 (de) 2003-12-15

Similar Documents

Publication Publication Date Title
CY2512B1 (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
JPH02184628A (ja) 関節炎疾患および炎症疾患に対する治療方法
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US5908857A (en) Agent for the treatment of infections
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
JPH02502278A (ja) とくに後天性免疫不全状態の処置のための、免疫調整及び抗ウイルス効果を有する医薬の調製におけるモルヒネ拮抗剤の使用
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
WO2016188091A1 (zh) 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
CA2795038C (en) Opioid receptor antagonist (naltrexone) for use in treating herpes zoster disease
NL8320239A (nl) Verbeterde analgetische en ontstekingsremmende preparaten met daarin ibuprofen, alsmede werkwijze voor het gebruik daarvan.
KR970061244A (ko) 치매 치료용 약학 조성물
JPH08283148A (ja) うつ性症状改善剤
JPH06500537A (ja) アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
ZA200404053B (en) Use of desoxypeganine for treating clinical depression.
DK175078B1 (da) Anvendelse af 15-deoxyspergualin til fremstilling af et lægemiddel til terapeutisk behandling af degenerative sygdomme i centralnervesystemet
CN112972462B (zh) 帕比司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用
CN112972448B (zh) 贝利司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用
JPH0415766B2 (de)
JPH04342528A (ja) アルコール代謝およびアセトアルデヒド代謝促進剤
JP2000186040A (ja) 抗ｈｉｖ感染症剤
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства
JP2729340B2 (ja) 痴呆症治療剤

Legal Events

Date Code Title Description
8363 Opposition against the patent